Spending power
TheGrid Corporate Spending Power index would rate purchasing capacity from registry, scale and activity signals.
Spending power
Key facts
Counted staff
87
self-reported 11–50 band
Founded
2001
25 years
Legal entities
1
ABR
Office countries
4
4 addresses
Funding rounds
None on record
Company type
Public Company
self-reported
Legal entity
1 brand → 1 confirmed entity
CLINUVEL PHARMACEUTICALS LIMITED
ABN88089644119
Legal entities
Show as table · CLINUVEL PHARMACEUTICALS LTD: 1 registry entity
| CLINUVEL PHARMACEUTICALS LIMITED | ABN 88089644119 |
|---|---|
| Confirmed matches | 0 of 1 |
A candidate is a name match on the registry, not a confirmed identity, and two candidates are ambiguity rather than a corporate structure.
Description
CLINUVEL PHARMACEUTICALS LTD (ASX: CUV; NASDAQ INTERNATIONAL DESIGNATION ADR: CLVLY; XETRA-DAX: UR9) is a global and diversified biopharmaceutical company focused on developing and commercialising treatments for patients with genetic, metabolic, and life-threatening disorders, as well as healthcare solutions for the general population. As pioneers in photomedicine and understanding the interaction of light and human biology, CLINUVEL’s research and development has led to innovative treatments for patient populations with a clinical need for systemic photoprotection, DNA repair and acute or life threatening conditions. These patient groups range in size from 5,000 to 45 million worldwide. CLINUVEL’s lead compound, SCENESSE® (afamelanotide 16mg), was approved by the European Commission in 2014 and the US Food and Drug Administration in 2019 for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). More information on EPP can be found at http://www.epp.care. Headquartered in Melbourne, Australia, CLINUVEL has operations in Europe, Singapore, and the USA. For more information please go to http://www.clinuvel.com.
SCENESSE® and PRÉNUMBRA® are registered trademarks of CLINUVEL PHARMACEUTICALS LTD
Specialties
All 9 specialties
- Drug development
- Drug commercialisation
- Photomedicine
- Rare diseases
- Pharmaceutical
- Photoprotection
- Erythropoietic protoporphyria
- Photocare
- Biotechnology
Locations
4
Countries with an office address4 addresses on record
Country footprint
Show as table · Offices in 4 countries
| Countries | 4 |
|---|---|
| Primary country | AU |
All codes: AU CH GB US
Addresses
- USPO Box 7388; Menlo Park, CA 94026
- CHZugerstrasse 76a; Baar, Zug 6340
- AULevel 22, 535 Bourke Street; Melbourne, Victoria 3000Primary
- GBThe Old Post Office; 33 Station Road; Egham, TW20 9LA
Grid intelligence Members
Signals & hiring
Hiring, headcount and registry-change signals, streamed to members.
Latest signal
Hiring activity
Headcount trend
Financials
Registry-filed capital and financial indicators, standardised by TheGrid.
Paid-up capital
Fiscal period
Registered charges
Revenue
Profit / loss
People & contacts
4 employee profiles on record · names withheld.
Names and titles are intentionally absent from this page. The source relation carries no consent record across the privacy regimes this directory spans, so it is never requested and never stored. Search engines see exactly what you see here.
Names are withheld until a consented source exists.
FAQ
Which legal entity operates under CLINUVEL PHARMACEUTICALS LTD?
One Victoria entity on the ABR: CLINUVEL PHARMACEUTICALS LIMITED (ABN 88 089 644 119), high confidence.
How many people work at CLINUVEL PHARMACEUTICALS LTD?
87 counted staff profiles at January 2026, above the self-reported 11–50 band.
Where does CLINUVEL PHARMACEUTICALS LTD have offices?
Four addresses on record across 4 countries. Primary: Level 22, 535 Bourke Street, Melbourne, Victoria 3000.
Has CLINUVEL PHARMACEUTICALS LTD raised funding?
None linked to this brand.
What does CLINUVEL PHARMACEUTICALS LTD list as its specialties?
Nine tags on the brand's own list, among them biotechnology and pharmaceutical.
Which companies are listed alongside CLINUVEL PHARMACEUTICALS LTD?
14 profiles list CLINUVEL PHARMACEUTICALS LTD as a peer — 88th percentile in Biotechnology Research. It lists ten peers of its own. Mesoblast Limited and Neuren Pharmaceuticals Limited list it back.